ArticleJournal of translational medicine2025
Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Clinical Prognostic Impact of CALLY in Heart Failure Patients With Different Ejection Fractions: A Retrospective Study.Reviews in cardiovascular medicine · 2026Article
- Prognostic value of the NAPLES score in patients undergoing LVAD implantation: comparison with established nutritional indices.BMC cardiovascular disorders · 2026Article
- Harnessing the novel safeguarding role of Selenoprotein T in age-related myocardial left and right decline through the ferroptosis-mitochondrial axis.Journal of translational medicine · 2026Article
- Diabetes-related differences in body composition and their prognostic value among patients with heart failure and preserved ejection fraction: a cardiac-MRI-based study.Cardiovascular diabetology · 2026Article
- Association between systemic immune-inflammation index(SII) and all-cause and cardiovascular mortality in heart failure patients: a single-center retrospective analysis.Frontiers in cardiovascular medicine · 2026Article
- Neutrophil-Percentage-to-Albumin Ratio Outperforms High-Sensitivity C-Reactive Protein in Predicting Mortality in Acute Heart Failure: Evidence from a Nationwide Prospective Cohort.Journal of inflammation research · 2026Article
- The association between systemic immune-inflammation index and mortality of elderly chronic bronchitis patients complicated by acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index.Frontiers in cardiovascular medicine · 2026Article
- The Systemic Immune-Inflammation Index as a Predictor of Clinical Outcomes in Chronic Coronary Syndrome: Influence of Diabetes Mellitus.Journal of inflammation research · 2026Article
- Comments on "Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction".Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) and preserved ejection fraction (HFpEF) represents a growing health burden characterized by systemic inflammation. Yet, reliable and cost-effective inflammatory biomarkers for risk stratification in HFpEF remain limited.
aimWe sought to examine the prognostic value of systemic immune-inflammation index (SII) on outcomes in HFpEF patients.
methodsThis study analyzed 458 (mean age:70.7 years; 59.2% women) participants with HFpEF admitted to the coronary care unit. HFpEF participants were grouped by SII values: Tertile 1 (SII ≤ 455.2), Tertile 2 (455.2-777.8), and Tertile 3 (SII > 777.8). Long-term associations between SII and composite outcomes, including all-cause, cardiovascular death, and HF rehospitalization, were evaluated. Decision curve analysis (DCA) assessed the clinical utility of SII-enhanced versus basic clinical models.
resultsBaseline demographics, comorbidities, and laboratory parameters varied significantly across SII tertiles. Of the total participants, 211 (46.1% ) experienced composite events over a mean follow-up of 41.8 months. When analyzed as a continuous variable, higher log-transformed SII was independently associated with increased risk of composite outcome of death and HF rehospitalization in the overall cohort (HR 1.50, 95% CI 1.18-1.92) and diabetic patients (HR 1.88, 95% CI 1.32-2.67), but not non-diabetic patients (HR 1.23, 95% CI 0.86-1.77) after multivariable adjustment. Similarly, in the fully adjusted tertile-based analysis, the highest SII tertile remained significantly associated with the composite outcome in the overall cohort (HR 1.70, 95% CI 1.15-2.52), with a particularly strong association observed in diabetic patients (HR 2.63, 95% CI 1.43-4.85), while no significant association was found in non-diabetic patients (HR 1.13, 95% CI 0.63-2.02). Restricted cubic splines demonstrated a linear relationship between SII and composite outcomes. SII showed superior prognostic accuracy compared to other inflammatory markers, and DCA confirmed improved clinical decision-making utility.
conclusionsIn patients with HFpEF, higher SII values were positively associated with risk of death and HF hospitalization, with particularly strong prognostic value in diabetic patients. SII represents a promising, accessible biomarker for enhanced risk stratification in HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.